nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—PSMB8—Estradiol valerate/Dienogest—Estradiol—osteoporosis	0.00328	0.366	CbGdCrCtD
Carfilzomib—PSMB8—Estradiol valerate/Dienogest—Ethinyl Estradiol—osteoporosis	0.0032	0.357	CbGdCrCtD
Carfilzomib—ABCB1—Ethinyl Estradiol—osteoporosis	0.00228	0.42	CbGbCtD
Carfilzomib—ABCB1—Conjugated Estrogens—osteoporosis	0.00168	0.309	CbGbCtD
Carfilzomib—ABCB1—Estradiol—osteoporosis	0.00147	0.271	CbGbCtD
Carfilzomib—PSMB8—Norethindrone—Ethinyl Estradiol—osteoporosis	0.00138	0.154	CbGdCrCtD
Carfilzomib—Cardiac disorder—Ibandronate—osteoporosis	0.00128	0.00347	CcSEcCtD
Carfilzomib—Pneumonia—Risedronate—osteoporosis	0.00128	0.00345	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Ethinyl Estradiol—osteoporosis	0.00127	0.00345	CcSEcCtD
Carfilzomib—Neutropenia—Pamidronate—osteoporosis	0.00126	0.00342	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Pamidronate—osteoporosis	0.00126	0.0034	CcSEcCtD
Carfilzomib—Hypokalaemia—Conjugated Estrogens—osteoporosis	0.00125	0.00339	CcSEcCtD
Carfilzomib—Chills—Ibandronate—osteoporosis	0.00124	0.00335	CcSEcCtD
Carfilzomib—Arthralgia—Etidronic acid—osteoporosis	0.00123	0.00334	CcSEcCtD
Carfilzomib—Diarrhoea—Calcium Acetate—osteoporosis	0.00123	0.00334	CcSEcCtD
Carfilzomib—Back pain—Estropipate—osteoporosis	0.00121	0.00328	CcSEcCtD
Carfilzomib—Pneumonia—Pamidronate—osteoporosis	0.00121	0.00328	CcSEcCtD
Carfilzomib—Muscle spasms—Estropipate—osteoporosis	0.00121	0.00326	CcSEcCtD
Carfilzomib—Dizziness—Calcium Acetate—osteoporosis	0.00119	0.00322	CcSEcCtD
Carfilzomib—Muscle spasms—Alendronate—osteoporosis	0.00119	0.00321	CcSEcCtD
Carfilzomib—Renal failure—Pamidronate—osteoporosis	0.00118	0.00321	CcSEcCtD
Carfilzomib—Infection—Etidronic acid—osteoporosis	0.00118	0.00318	CcSEcCtD
Carfilzomib—Muscle spasms—Raloxifene—osteoporosis	0.00117	0.00316	CcSEcCtD
Carfilzomib—Back pain—Ibandronate—osteoporosis	0.00116	0.00315	CcSEcCtD
Carfilzomib—Hypoaesthesia—Ethinyl Estradiol—osteoporosis	0.00116	0.00314	CcSEcCtD
Carfilzomib—Muscle spasms—Ibandronate—osteoporosis	0.00116	0.00313	CcSEcCtD
Carfilzomib—Neutropenia—Zoledronate—osteoporosis	0.00115	0.00312	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Zoledronate—osteoporosis	0.00115	0.00311	CcSEcCtD
Carfilzomib—Vomiting—Calcium Acetate—osteoporosis	0.00115	0.0031	CcSEcCtD
Carfilzomib—Asthenia—Ergocalciferol—osteoporosis	0.00114	0.00309	CcSEcCtD
Carfilzomib—Anaemia—Alendronate—osteoporosis	0.00114	0.00309	CcSEcCtD
Carfilzomib—Oedema peripheral—Risedronate—osteoporosis	0.00112	0.00303	CcSEcCtD
Carfilzomib—Anaemia—Ibandronate—osteoporosis	0.00111	0.00301	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Conjugated Estrogens—osteoporosis	0.00111	0.00299	CcSEcCtD
Carfilzomib—Pain in extremity—Estradiol—osteoporosis	0.0011	0.00298	CcSEcCtD
Carfilzomib—PSMB8—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.0011	0.122	CbGdCrCtD
Carfilzomib—Cough—Estropipate—osteoporosis	0.00109	0.00296	CcSEcCtD
Carfilzomib—Renal failure—Zoledronate—osteoporosis	0.00108	0.00293	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Etidronic acid—osteoporosis	0.00108	0.00292	CcSEcCtD
Carfilzomib—Hyperglycaemia—Conjugated Estrogens—osteoporosis	0.00107	0.0029	CcSEcCtD
Carfilzomib—Nausea—Calcium Acetate—osteoporosis	0.00107	0.0029	CcSEcCtD
Carfilzomib—Arthralgia—Estropipate—osteoporosis	0.00107	0.00289	CcSEcCtD
Carfilzomib—Cough—Raloxifene—osteoporosis	0.00106	0.00287	CcSEcCtD
Carfilzomib—Cardiac disorder—Risedronate—osteoporosis	0.00106	0.00286	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Conjugated Estrogens—osteoporosis	0.00105	0.00283	CcSEcCtD
Carfilzomib—Renal failure—Conjugated Estrogens—osteoporosis	0.00104	0.00282	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Conjugated Estrogens—osteoporosis	0.00104	0.00281	CcSEcCtD
Carfilzomib—Hypertension—Ibandronate—osteoporosis	0.00104	0.00281	CcSEcCtD
Carfilzomib—Arthralgia—Raloxifene—osteoporosis	0.00103	0.0028	CcSEcCtD
Carfilzomib—Arthralgia—Ibandronate—osteoporosis	0.00102	0.00277	CcSEcCtD
Carfilzomib—Infection—Estropipate—osteoporosis	0.00102	0.00275	CcSEcCtD
Carfilzomib—Hypertension—Calcitriol—osteoporosis	0.00102	0.00275	CcSEcCtD
Carfilzomib—Constipation—Etidronic acid—osteoporosis	0.00101	0.00274	CcSEcCtD
Carfilzomib—Cardiac disorder—Pamidronate—osteoporosis	0.001	0.00272	CcSEcCtD
Carfilzomib—Infection—Alendronate—osteoporosis	0.001	0.00271	CcSEcCtD
Carfilzomib—Infection—Raloxifene—osteoporosis	0.000985	0.00267	CcSEcCtD
Carfilzomib—Hypoaesthesia—Zoledronate—osteoporosis	0.000983	0.00266	CcSEcCtD
Carfilzomib—Back pain—Ethinyl Estradiol—osteoporosis	0.000983	0.00266	CcSEcCtD
Carfilzomib—Muscle spasms—Ethinyl Estradiol—osteoporosis	0.000977	0.00264	CcSEcCtD
Carfilzomib—Infection—Ibandronate—osteoporosis	0.000975	0.00264	CcSEcCtD
Carfilzomib—Oedema peripheral—Zoledronate—osteoporosis	0.000974	0.00264	CcSEcCtD
Carfilzomib—Chills—Pamidronate—osteoporosis	0.000971	0.00263	CcSEcCtD
Carfilzomib—Thrombocytopenia—Raloxifene—osteoporosis	0.000971	0.00263	CcSEcCtD
Carfilzomib—Back pain—Risedronate—osteoporosis	0.000959	0.00259	CcSEcCtD
Carfilzomib—Muscle spasms—Risedronate—osteoporosis	0.000953	0.00258	CcSEcCtD
Carfilzomib—Hypoaesthesia—Conjugated Estrogens—osteoporosis	0.000947	0.00256	CcSEcCtD
Carfilzomib—Nausea—Ergocalciferol—osteoporosis	0.000945	0.00256	CcSEcCtD
Carfilzomib—Oedema peripheral—Conjugated Estrogens—osteoporosis	0.000938	0.00254	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Estropipate—osteoporosis	0.000932	0.00252	CcSEcCtD
Carfilzomib—Insomnia—Estropipate—osteoporosis	0.000926	0.0025	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Alendronate—osteoporosis	0.000918	0.00249	CcSEcCtD
Carfilzomib—Cardiac disorder—Zoledronate—osteoporosis	0.000917	0.00248	CcSEcCtD
Carfilzomib—Anaemia—Risedronate—osteoporosis	0.000916	0.00248	CcSEcCtD
Carfilzomib—Anorexia—Calcitriol—osteoporosis	0.000916	0.00248	CcSEcCtD
Carfilzomib—Back pain—Pamidronate—osteoporosis	0.000911	0.00247	CcSEcCtD
Carfilzomib—Muscle spasms—Pamidronate—osteoporosis	0.000906	0.00245	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Raloxifene—osteoporosis	0.000903	0.00244	CcSEcCtD
Carfilzomib—Insomnia—Raloxifene—osteoporosis	0.000897	0.00243	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Ibandronate—osteoporosis	0.000894	0.00242	CcSEcCtD
Carfilzomib—Insomnia—Ibandronate—osteoporosis	0.000888	0.0024	CcSEcCtD
Carfilzomib—Chills—Zoledronate—osteoporosis	0.000887	0.0024	CcSEcCtD
Carfilzomib—Cough—Ethinyl Estradiol—osteoporosis	0.000887	0.0024	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Estradiol—osteoporosis	0.000884	0.00239	CcSEcCtD
Carfilzomib—Cardiac disorder—Conjugated Estrogens—osteoporosis	0.000883	0.00239	CcSEcCtD
Carfilzomib—Fatigue—Estropipate—osteoporosis	0.000882	0.00239	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.000875	0.00237	CcSEcCtD
Carfilzomib—Pain—Estropipate—osteoporosis	0.000875	0.00237	CcSEcCtD
Carfilzomib—Constipation—Estropipate—osteoporosis	0.000875	0.00237	CcSEcCtD
Carfilzomib—Anaemia—Pamidronate—osteoporosis	0.000871	0.00236	CcSEcCtD
Carfilzomib—Insomnia—Calcitriol—osteoporosis	0.000869	0.00235	CcSEcCtD
Carfilzomib—Cough—Risedronate—osteoporosis	0.000865	0.00234	CcSEcCtD
Carfilzomib—Pain—Alendronate—osteoporosis	0.000862	0.00233	CcSEcCtD
Carfilzomib—Constipation—Alendronate—osteoporosis	0.000862	0.00233	CcSEcCtD
Carfilzomib—Hyperglycaemia—Estradiol—osteoporosis	0.000858	0.00232	CcSEcCtD
Carfilzomib—Hypertension—Risedronate—osteoporosis	0.000856	0.00232	CcSEcCtD
Carfilzomib—Pneumonia—Estradiol—osteoporosis	0.000853	0.00231	CcSEcCtD
Carfilzomib—Decreased appetite—Ibandronate—osteoporosis	0.000853	0.00231	CcSEcCtD
Carfilzomib—Pain—Raloxifene—osteoporosis	0.000848	0.00229	CcSEcCtD
Carfilzomib—Fatigue—Ibandronate—osteoporosis	0.000846	0.00229	CcSEcCtD
Carfilzomib—Arthralgia—Risedronate—osteoporosis	0.000844	0.00228	CcSEcCtD
Carfilzomib—Leukopenia—Pamidronate—osteoporosis	0.000843	0.00228	CcSEcCtD
Carfilzomib—Pain—Ibandronate—osteoporosis	0.000839	0.00227	CcSEcCtD
Carfilzomib—Constipation—Ibandronate—osteoporosis	0.000839	0.00227	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Estradiol—osteoporosis	0.000836	0.00226	CcSEcCtD
Carfilzomib—Decreased appetite—Calcitriol—osteoporosis	0.000835	0.00226	CcSEcCtD
Carfilzomib—Back pain—Zoledronate—osteoporosis	0.000832	0.00225	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Estradiol—osteoporosis	0.000832	0.00225	CcSEcCtD
Carfilzomib—Muscle spasms—Zoledronate—osteoporosis	0.000827	0.00224	CcSEcCtD
Carfilzomib—Infection—Ethinyl Estradiol—osteoporosis	0.000824	0.00223	CcSEcCtD
Carfilzomib—Cough—Pamidronate—osteoporosis	0.000822	0.00222	CcSEcCtD
Carfilzomib—Pain—Calcitriol—osteoporosis	0.000821	0.00222	CcSEcCtD
Carfilzomib—Constipation—Calcitriol—osteoporosis	0.000821	0.00222	CcSEcCtD
Carfilzomib—Hypertension—Pamidronate—osteoporosis	0.000813	0.0022	CcSEcCtD
Carfilzomib—Diarrhoea—Etidronic acid—osteoporosis	0.000809	0.00219	CcSEcCtD
Carfilzomib—Body temperature increased—Estropipate—osteoporosis	0.000809	0.00219	CcSEcCtD
Carfilzomib—Infection—Risedronate—osteoporosis	0.000803	0.00217	CcSEcCtD
Carfilzomib—Arthralgia—Pamidronate—osteoporosis	0.000802	0.00217	CcSEcCtD
Carfilzomib—Back pain—Conjugated Estrogens—osteoporosis	0.000801	0.00217	CcSEcCtD
Carfilzomib—Body temperature increased—Alendronate—osteoporosis	0.000797	0.00216	CcSEcCtD
Carfilzomib—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000797	0.00216	CcSEcCtD
Carfilzomib—Anaemia—Zoledronate—osteoporosis	0.000795	0.00215	CcSEcCtD
Carfilzomib—Body temperature increased—Raloxifene—osteoporosis	0.000784	0.00212	CcSEcCtD
Carfilzomib—Body temperature increased—Ibandronate—osteoporosis	0.000776	0.0021	CcSEcCtD
Carfilzomib—Leukopenia—Zoledronate—osteoporosis	0.00077	0.00208	CcSEcCtD
Carfilzomib—Infection—Pamidronate—osteoporosis	0.000764	0.00207	CcSEcCtD
Carfilzomib—Body temperature increased—Calcitriol—osteoporosis	0.000759	0.00206	CcSEcCtD
Carfilzomib—Hypoaesthesia—Estradiol—osteoporosis	0.000758	0.00205	CcSEcCtD
Carfilzomib—Thrombocytopenia—Pamidronate—osteoporosis	0.000753	0.00204	CcSEcCtD
Carfilzomib—Vomiting—Etidronic acid—osteoporosis	0.000752	0.00204	CcSEcCtD
Carfilzomib—Cough—Zoledronate—osteoporosis	0.000751	0.00203	CcSEcCtD
Carfilzomib—Oedema peripheral—Estradiol—osteoporosis	0.00075	0.00203	CcSEcCtD
Carfilzomib—Hypertension—Zoledronate—osteoporosis	0.000743	0.00201	CcSEcCtD
Carfilzomib—Headache—Etidronic acid—osteoporosis	0.000741	0.00201	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000737	0.00199	CcSEcCtD
Carfilzomib—Asthenia—Estropipate—osteoporosis	0.000734	0.00199	CcSEcCtD
Carfilzomib—Anorexia—Pamidronate—osteoporosis	0.000733	0.00198	CcSEcCtD
Carfilzomib—Arthralgia—Zoledronate—osteoporosis	0.000733	0.00198	CcSEcCtD
Carfilzomib—Insomnia—Risedronate—osteoporosis	0.000731	0.00198	CcSEcCtD
Carfilzomib—Asthenia—Alendronate—osteoporosis	0.000723	0.00196	CcSEcCtD
Carfilzomib—Cough—Conjugated Estrogens—osteoporosis	0.000723	0.00196	CcSEcCtD
Carfilzomib—Dyspnoea—Risedronate—osteoporosis	0.000721	0.00195	CcSEcCtD
Carfilzomib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000715	0.00194	CcSEcCtD
Carfilzomib—Constipation—Ethinyl Estradiol—osteoporosis	0.000709	0.00192	CcSEcCtD
Carfilzomib—Cardiac disorder—Estradiol—osteoporosis	0.000707	0.00191	CcSEcCtD
Carfilzomib—Arthralgia—Conjugated Estrogens—osteoporosis	0.000705	0.00191	CcSEcCtD
Carfilzomib—Asthenia—Ibandronate—osteoporosis	0.000704	0.00191	CcSEcCtD
Carfilzomib—Nausea—Etidronic acid—osteoporosis	0.000703	0.0019	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.0007	0.0019	CcSEcCtD
Carfilzomib—Diarrhoea—Estropipate—osteoporosis	0.0007	0.00189	CcSEcCtD
Carfilzomib—Infection—Zoledronate—osteoporosis	0.000698	0.00189	CcSEcCtD
Carfilzomib—Fatigue—Risedronate—osteoporosis	0.000697	0.00189	CcSEcCtD
Carfilzomib—Insomnia—Pamidronate—osteoporosis	0.000695	0.00188	CcSEcCtD
Carfilzomib—Pain—Risedronate—osteoporosis	0.000692	0.00187	CcSEcCtD
Carfilzomib—Constipation—Risedronate—osteoporosis	0.000692	0.00187	CcSEcCtD
Carfilzomib—Diarrhoea—Alendronate—osteoporosis	0.00069	0.00187	CcSEcCtD
Carfilzomib—Asthenia—Calcitriol—osteoporosis	0.000689	0.00187	CcSEcCtD
Carfilzomib—Thrombocytopenia—Zoledronate—osteoporosis	0.000688	0.00186	CcSEcCtD
Carfilzomib—Dyspnoea—Pamidronate—osteoporosis	0.000685	0.00185	CcSEcCtD
Carfilzomib—Chills—Estradiol—osteoporosis	0.000683	0.00185	CcSEcCtD
Carfilzomib—Diarrhoea—Raloxifene—osteoporosis	0.000678	0.00184	CcSEcCtD
Carfilzomib—Dizziness—Estropipate—osteoporosis	0.000677	0.00183	CcSEcCtD
Carfilzomib—Infection—Conjugated Estrogens—osteoporosis	0.000672	0.00182	CcSEcCtD
Carfilzomib—Diarrhoea—Ibandronate—osteoporosis	0.000671	0.00182	CcSEcCtD
Carfilzomib—Anorexia—Zoledronate—osteoporosis	0.000669	0.00181	CcSEcCtD
Carfilzomib—Decreased appetite—Pamidronate—osteoporosis	0.000668	0.00181	CcSEcCtD
Carfilzomib—Dizziness—Alendronate—osteoporosis	0.000667	0.0018	CcSEcCtD
Carfilzomib—Fatigue—Pamidronate—osteoporosis	0.000663	0.00179	CcSEcCtD
Carfilzomib—Pain—Pamidronate—osteoporosis	0.000657	0.00178	CcSEcCtD
Carfilzomib—Constipation—Pamidronate—osteoporosis	0.000657	0.00178	CcSEcCtD
Carfilzomib—Diarrhoea—Calcitriol—osteoporosis	0.000657	0.00178	CcSEcCtD
Carfilzomib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000656	0.00177	CcSEcCtD
Carfilzomib—Dizziness—Raloxifene—osteoporosis	0.000656	0.00177	CcSEcCtD
Carfilzomib—Vomiting—Estropipate—osteoporosis	0.000651	0.00176	CcSEcCtD
Carfilzomib—Dizziness—Ibandronate—osteoporosis	0.000649	0.00176	CcSEcCtD
Carfilzomib—Anorexia—Conjugated Estrogens—osteoporosis	0.000645	0.00174	CcSEcCtD
Carfilzomib—Back pain—Estradiol—osteoporosis	0.000641	0.00174	CcSEcCtD
Carfilzomib—Headache—Estropipate—osteoporosis	0.000641	0.00173	CcSEcCtD
Carfilzomib—Vomiting—Alendronate—osteoporosis	0.000641	0.00173	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.00064	0.00173	CcSEcCtD
Carfilzomib—Body temperature increased—Risedronate—osteoporosis	0.000639	0.00173	CcSEcCtD
Carfilzomib—Muscle spasms—Estradiol—osteoporosis	0.000638	0.00173	CcSEcCtD
Carfilzomib—Insomnia—Zoledronate—osteoporosis	0.000635	0.00172	CcSEcCtD
Carfilzomib—Headache—Alendronate—osteoporosis	0.000631	0.00171	CcSEcCtD
Carfilzomib—Vomiting—Raloxifene—osteoporosis	0.00063	0.00171	CcSEcCtD
Carfilzomib—Dyspnoea—Zoledronate—osteoporosis	0.000626	0.00169	CcSEcCtD
Carfilzomib—Vomiting—Ibandronate—osteoporosis	0.000624	0.00169	CcSEcCtD
Carfilzomib—Headache—Raloxifene—osteoporosis	0.000621	0.00168	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000616	0.00167	CcSEcCtD
Carfilzomib—Headache—Ibandronate—osteoporosis	0.000615	0.00166	CcSEcCtD
Carfilzomib—Insomnia—Conjugated Estrogens—osteoporosis	0.000612	0.00166	CcSEcCtD
Carfilzomib—Vomiting—Calcitriol—osteoporosis	0.000611	0.00165	CcSEcCtD
Carfilzomib—Decreased appetite—Zoledronate—osteoporosis	0.00061	0.00165	CcSEcCtD
Carfilzomib—Nausea—Estropipate—osteoporosis	0.000608	0.00164	CcSEcCtD
Carfilzomib—Body temperature increased—Pamidronate—osteoporosis	0.000608	0.00164	CcSEcCtD
Carfilzomib—Fatigue—Zoledronate—osteoporosis	0.000605	0.00164	CcSEcCtD
Carfilzomib—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000603	0.00163	CcSEcCtD
Carfilzomib—Headache—Calcitriol—osteoporosis	0.000602	0.00163	CcSEcCtD
Carfilzomib—Constipation—Zoledronate—osteoporosis	0.000601	0.00163	CcSEcCtD
Carfilzomib—Pain—Zoledronate—osteoporosis	0.000601	0.00163	CcSEcCtD
Carfilzomib—Nausea—Alendronate—osteoporosis	0.000599	0.00162	CcSEcCtD
Carfilzomib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000595	0.00161	CcSEcCtD
Carfilzomib—Nausea—Raloxifene—osteoporosis	0.000589	0.00159	CcSEcCtD
Carfilzomib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000588	0.00159	CcSEcCtD
Carfilzomib—Fatigue—Conjugated Estrogens—osteoporosis	0.000583	0.00158	CcSEcCtD
Carfilzomib—Nausea—Ibandronate—osteoporosis	0.000583	0.00158	CcSEcCtD
Carfilzomib—Asthenia—Risedronate—osteoporosis	0.00058	0.00157	CcSEcCtD
Carfilzomib—Cough—Estradiol—osteoporosis	0.000579	0.00157	CcSEcCtD
Carfilzomib—Pain—Conjugated Estrogens—osteoporosis	0.000578	0.00156	CcSEcCtD
Carfilzomib—Constipation—Conjugated Estrogens—osteoporosis	0.000578	0.00156	CcSEcCtD
Carfilzomib—Hypertension—Estradiol—osteoporosis	0.000572	0.00155	CcSEcCtD
Carfilzomib—Nausea—Calcitriol—osteoporosis	0.000571	0.00154	CcSEcCtD
Carfilzomib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000568	0.00154	CcSEcCtD
Carfilzomib—Arthralgia—Estradiol—osteoporosis	0.000565	0.00153	CcSEcCtD
Carfilzomib—Body temperature increased—Zoledronate—osteoporosis	0.000555	0.0015	CcSEcCtD
Carfilzomib—Diarrhoea—Risedronate—osteoporosis	0.000553	0.0015	CcSEcCtD
Carfilzomib—Asthenia—Pamidronate—osteoporosis	0.000552	0.00149	CcSEcCtD
Carfilzomib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000549	0.00148	CcSEcCtD
Carfilzomib—Infection—Estradiol—osteoporosis	0.000538	0.00145	CcSEcCtD
Carfilzomib—Dizziness—Risedronate—osteoporosis	0.000535	0.00145	CcSEcCtD
Carfilzomib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000535	0.00145	CcSEcCtD
Carfilzomib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000527	0.00143	CcSEcCtD
Carfilzomib—Diarrhoea—Pamidronate—osteoporosis	0.000526	0.00142	CcSEcCtD
Carfilzomib—Headache—Ethinyl Estradiol—osteoporosis	0.00052	0.00141	CcSEcCtD
Carfilzomib—Vomiting—Risedronate—osteoporosis	0.000514	0.00139	CcSEcCtD
Carfilzomib—Dizziness—Pamidronate—osteoporosis	0.000508	0.00138	CcSEcCtD
Carfilzomib—Headache—Risedronate—osteoporosis	0.000507	0.00137	CcSEcCtD
Carfilzomib—Asthenia—Zoledronate—osteoporosis	0.000504	0.00136	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000493	0.00133	CcSEcCtD
Carfilzomib—Nausea—Ethinyl Estradiol—osteoporosis	0.000493	0.00133	CcSEcCtD
Carfilzomib—Insomnia—Estradiol—osteoporosis	0.000489	0.00132	CcSEcCtD
Carfilzomib—Vomiting—Pamidronate—osteoporosis	0.000489	0.00132	CcSEcCtD
Carfilzomib—Asthenia—Conjugated Estrogens—osteoporosis	0.000485	0.00131	CcSEcCtD
Carfilzomib—Dyspnoea—Estradiol—osteoporosis	0.000482	0.00131	CcSEcCtD
Carfilzomib—Headache—Pamidronate—osteoporosis	0.000482	0.0013	CcSEcCtD
Carfilzomib—Diarrhoea—Zoledronate—osteoporosis	0.00048	0.0013	CcSEcCtD
Carfilzomib—Nausea—Risedronate—osteoporosis	0.00048	0.0013	CcSEcCtD
Carfilzomib—Decreased appetite—Estradiol—osteoporosis	0.00047	0.00127	CcSEcCtD
Carfilzomib—Fatigue—Estradiol—osteoporosis	0.000467	0.00126	CcSEcCtD
Carfilzomib—Dizziness—Zoledronate—osteoporosis	0.000464	0.00126	CcSEcCtD
Carfilzomib—Constipation—Estradiol—osteoporosis	0.000463	0.00125	CcSEcCtD
Carfilzomib—Pain—Estradiol—osteoporosis	0.000463	0.00125	CcSEcCtD
Carfilzomib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000463	0.00125	CcSEcCtD
Carfilzomib—Nausea—Pamidronate—osteoporosis	0.000457	0.00124	CcSEcCtD
Carfilzomib—Dizziness—Conjugated Estrogens—osteoporosis	0.000447	0.00121	CcSEcCtD
Carfilzomib—Vomiting—Zoledronate—osteoporosis	0.000447	0.00121	CcSEcCtD
Carfilzomib—Headache—Zoledronate—osteoporosis	0.00044	0.00119	CcSEcCtD
Carfilzomib—Vomiting—Conjugated Estrogens—osteoporosis	0.00043	0.00116	CcSEcCtD
Carfilzomib—Body temperature increased—Estradiol—osteoporosis	0.000428	0.00116	CcSEcCtD
Carfilzomib—Headache—Conjugated Estrogens—osteoporosis	0.000424	0.00115	CcSEcCtD
Carfilzomib—Nausea—Zoledronate—osteoporosis	0.000417	0.00113	CcSEcCtD
Carfilzomib—Nausea—Conjugated Estrogens—osteoporosis	0.000402	0.00109	CcSEcCtD
Carfilzomib—Asthenia—Estradiol—osteoporosis	0.000388	0.00105	CcSEcCtD
Carfilzomib—Diarrhoea—Estradiol—osteoporosis	0.00037	0.001	CcSEcCtD
Carfilzomib—Dizziness—Estradiol—osteoporosis	0.000358	0.000968	CcSEcCtD
Carfilzomib—Vomiting—Estradiol—osteoporosis	0.000344	0.000931	CcSEcCtD
Carfilzomib—Headache—Estradiol—osteoporosis	0.000339	0.000917	CcSEcCtD
Carfilzomib—Nausea—Estradiol—osteoporosis	0.000321	0.00087	CcSEcCtD
Carfilzomib—PSMB8—Signaling Pathways—BMP2—osteoporosis	3.87e-05	6.28e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—GPX1—osteoporosis	3.87e-05	6.28e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—ADCY5—osteoporosis	3.86e-05	6.27e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—GPX1—osteoporosis	3.85e-05	6.25e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—FGB—osteoporosis	3.84e-05	6.24e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—FGB—osteoporosis	3.84e-05	6.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—FGB—osteoporosis	3.84e-05	6.24e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—MYC—osteoporosis	3.84e-05	6.23e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IRS1—osteoporosis	3.83e-05	6.22e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—MYC—osteoporosis	3.82e-05	6.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AGER—osteoporosis	3.82e-05	6.19e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AGER—osteoporosis	3.82e-05	6.19e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AGER—osteoporosis	3.82e-05	6.19e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IRS1—osteoporosis	3.81e-05	6.19e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—ADCY5—osteoporosis	3.8e-05	6.17e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—ADCY5—osteoporosis	3.8e-05	6.17e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—ADCY5—osteoporosis	3.8e-05	6.17e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	3.8e-05	6.17e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—FGB—osteoporosis	3.79e-05	6.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AGER—osteoporosis	3.76e-05	6.11e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—ADCY5—osteoporosis	3.75e-05	6.09e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—TNF—osteoporosis	3.73e-05	6.06e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PSMA2—osteoporosis	3.71e-05	6.02e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PSMA2—osteoporosis	3.71e-05	6.02e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PSMA5—osteoporosis	3.71e-05	6.02e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PSMA5—osteoporosis	3.71e-05	6.02e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PSMA5—osteoporosis	3.71e-05	6.02e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PSMA2—osteoporosis	3.71e-05	6.02e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL6—osteoporosis	3.67e-05	5.96e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PSMA5—osteoporosis	3.66e-05	5.94e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PSMA2—osteoporosis	3.66e-05	5.94e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6R—osteoporosis	3.6e-05	5.84e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—CYP19A1—osteoporosis	3.6e-05	5.84e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—CYP19A1—osteoporosis	3.6e-05	5.84e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—CYP19A1—osteoporosis	3.6e-05	5.84e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6R—osteoporosis	3.58e-05	5.82e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—MTHFR—osteoporosis	3.57e-05	5.79e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—MTHFR—osteoporosis	3.55e-05	5.76e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—CYP19A1—osteoporosis	3.55e-05	5.76e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IRS1—osteoporosis	3.54e-05	5.74e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IRS1—osteoporosis	3.52e-05	5.72e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—ADCY5—osteoporosis	3.51e-05	5.7e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—ADCY5—osteoporosis	3.51e-05	5.7e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—ADCY5—osteoporosis	3.51e-05	5.7e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PKM—osteoporosis	3.51e-05	5.7e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—FDPS—osteoporosis	3.51e-05	5.7e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—ADCY5—osteoporosis	3.46e-05	5.62e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CALCA—osteoporosis	3.46e-05	5.61e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CALCA—osteoporosis	3.46e-05	5.61e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CALCA—osteoporosis	3.46e-05	5.61e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CALCA—osteoporosis	3.41e-05	5.53e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IRS2—osteoporosis	3.33e-05	5.4e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IRS2—osteoporosis	3.33e-05	5.4e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IRS2—osteoporosis	3.33e-05	5.4e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GPD2—osteoporosis	3.33e-05	5.4e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PGLS—osteoporosis	3.33e-05	5.4e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6R—osteoporosis	3.32e-05	5.4e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6R—osteoporosis	3.31e-05	5.37e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	3.29e-05	5.34e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IRS2—osteoporosis	3.28e-05	5.32e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—MYC—osteoporosis	3.25e-05	5.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—MYC—osteoporosis	3.25e-05	5.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—MYC—osteoporosis	3.25e-05	5.28e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—ADCY5—osteoporosis	3.24e-05	5.27e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MTHFR—osteoporosis	3.23e-05	5.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MTHFR—osteoporosis	3.23e-05	5.24e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MTHFR—osteoporosis	3.23e-05	5.24e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—ADCY5—osteoporosis	3.23e-05	5.24e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—MYC—osteoporosis	3.21e-05	5.21e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MTHFR—osteoporosis	3.18e-05	5.17e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KL—osteoporosis	3.14e-05	5.09e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KL—osteoporosis	3.14e-05	5.09e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KL—osteoporosis	3.14e-05	5.09e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SPP1—osteoporosis	3.14e-05	5.09e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SPP1—osteoporosis	3.12e-05	5.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KL—osteoporosis	3.09e-05	5.02e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—ESR1—osteoporosis	3.09e-05	5.02e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—ESR1—osteoporosis	3.09e-05	5.02e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—ESR1—osteoporosis	3.09e-05	5.02e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IRS2—osteoporosis	3.07e-05	4.99e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IRS2—osteoporosis	3.07e-05	4.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IRS2—osteoporosis	3.07e-05	4.99e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—ESR1—osteoporosis	3.05e-05	4.95e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ATIC—osteoporosis	3.04e-05	4.94e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PNP—osteoporosis	3.04e-05	4.94e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IRS2—osteoporosis	3.03e-05	4.92e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—ADCY5—osteoporosis	2.94e-05	4.77e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—ADCY5—osteoporosis	2.94e-05	4.77e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—ADCY5—osteoporosis	2.94e-05	4.77e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—GPX1—osteoporosis	2.93e-05	4.76e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—GPX1—osteoporosis	2.93e-05	4.76e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—GPX1—osteoporosis	2.93e-05	4.76e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—MYC—osteoporosis	2.91e-05	4.72e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—MYC—osteoporosis	2.91e-05	4.72e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—MYC—osteoporosis	2.91e-05	4.72e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IRS1—osteoporosis	2.9e-05	4.71e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IRS1—osteoporosis	2.9e-05	4.71e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IRS1—osteoporosis	2.9e-05	4.71e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—ADCY5—osteoporosis	2.9e-05	4.71e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—GPX1—osteoporosis	2.89e-05	4.69e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—MYC—osteoporosis	2.87e-05	4.66e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IRS1—osteoporosis	2.86e-05	4.65e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—POMC—osteoporosis	2.85e-05	4.63e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—POMC—osteoporosis	2.84e-05	4.61e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IRS2—osteoporosis	2.84e-05	4.61e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IRS2—osteoporosis	2.83e-05	4.59e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—LEP—osteoporosis	2.78e-05	4.51e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—LEP—osteoporosis	2.76e-05	4.49e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL1B—osteoporosis	2.74e-05	4.45e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6R—osteoporosis	2.73e-05	4.43e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6R—osteoporosis	2.73e-05	4.43e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6R—osteoporosis	2.73e-05	4.43e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL1B—osteoporosis	2.73e-05	4.42e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—MTHFR—osteoporosis	2.7e-05	4.39e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—MTHFR—osteoporosis	2.7e-05	4.39e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—MTHFR—osteoporosis	2.7e-05	4.39e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6R—osteoporosis	2.69e-05	4.37e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IRS1—osteoporosis	2.68e-05	4.35e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IRS1—osteoporosis	2.68e-05	4.35e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IRS1—osteoporosis	2.68e-05	4.35e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—MTHFR—osteoporosis	2.67e-05	4.33e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—ESR1—osteoporosis	2.65e-05	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IRS1—osteoporosis	2.64e-05	4.29e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—ESR1—osteoporosis	2.64e-05	4.28e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CA2—osteoporosis	2.59e-05	4.2e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—OXCT1—osteoporosis	2.59e-05	4.2e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MGLL—osteoporosis	2.52e-05	4.09e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6R—osteoporosis	2.52e-05	4.09e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6R—osteoporosis	2.52e-05	4.09e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6R—osteoporosis	2.52e-05	4.09e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6R—osteoporosis	2.48e-05	4.03e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IRS1—osteoporosis	2.48e-05	4.02e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IRS1—osteoporosis	2.47e-05	4e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ADCY5—osteoporosis	2.46e-05	3.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ADCY5—osteoporosis	2.46e-05	3.99e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ADCY5—osteoporosis	2.46e-05	3.99e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ADCY5—osteoporosis	2.42e-05	3.93e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—POMC—osteoporosis	2.39e-05	3.87e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SPP1—osteoporosis	2.38e-05	3.86e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SPP1—osteoporosis	2.38e-05	3.86e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SPP1—osteoporosis	2.38e-05	3.86e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—POMC—osteoporosis	2.37e-05	3.85e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SPP1—osteoporosis	2.35e-05	3.81e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6R—osteoporosis	2.33e-05	3.78e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6R—osteoporosis	2.32e-05	3.76e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IGF1—osteoporosis	2.3e-05	3.73e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IGF1—osteoporosis	2.28e-05	3.71e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—POMC—osteoporosis	2.16e-05	3.51e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—POMC—osteoporosis	2.16e-05	3.51e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—POMC—osteoporosis	2.16e-05	3.51e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IRS2—osteoporosis	2.15e-05	3.49e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IRS2—osteoporosis	2.15e-05	3.49e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IRS2—osteoporosis	2.15e-05	3.49e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—IDH2—osteoporosis	2.14e-05	3.48e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—POMC—osteoporosis	2.13e-05	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—MYC—osteoporosis	2.12e-05	3.44e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IRS2—osteoporosis	2.12e-05	3.44e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—MYC—osteoporosis	2.11e-05	3.43e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—LEP—osteoporosis	2.11e-05	3.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—LEP—osteoporosis	2.11e-05	3.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—LEP—osteoporosis	2.11e-05	3.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL1B—osteoporosis	2.08e-05	3.37e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL1B—osteoporosis	2.08e-05	3.37e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL1B—osteoporosis	2.08e-05	3.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—LEP—osteoporosis	2.08e-05	3.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL1B—osteoporosis	2.05e-05	3.32e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP27A1—osteoporosis	2.02e-05	3.27e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ESR1—osteoporosis	2.01e-05	3.26e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ESR1—osteoporosis	2.01e-05	3.26e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ESR1—osteoporosis	2.01e-05	3.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ESR1—osteoporosis	1.98e-05	3.22e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.98e-05	3.21e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.97e-05	3.2e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MYC—osteoporosis	1.97e-05	3.2e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—TGFB1—osteoporosis	1.97e-05	3.19e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ACP5—osteoporosis	1.96e-05	3.18e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MYC—osteoporosis	1.96e-05	3.18e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—TGFB1—osteoporosis	1.96e-05	3.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IRS1—osteoporosis	1.88e-05	3.05e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IRS1—osteoporosis	1.88e-05	3.05e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IRS1—osteoporosis	1.88e-05	3.05e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IRS1—osteoporosis	1.85e-05	3.01e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.85e-05	3e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.84e-05	2.99e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TPI1—osteoporosis	1.82e-05	2.96e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—POMC—osteoporosis	1.81e-05	2.94e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—POMC—osteoporosis	1.81e-05	2.94e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—POMC—osteoporosis	1.81e-05	2.94e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—POMC—osteoporosis	1.78e-05	2.89e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6R—osteoporosis	1.76e-05	2.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6R—osteoporosis	1.76e-05	2.86e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6R—osteoporosis	1.76e-05	2.86e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IGF1—osteoporosis	1.74e-05	2.82e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IGF1—osteoporosis	1.74e-05	2.82e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IGF1—osteoporosis	1.74e-05	2.82e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6R—osteoporosis	1.74e-05	2.82e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IGF1—osteoporosis	1.72e-05	2.78e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—P4HB—osteoporosis	1.71e-05	2.78e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GAPDH—osteoporosis	1.68e-05	2.73e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—RAP1A—osteoporosis	1.64e-05	2.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—osteoporosis	1.61e-05	2.61e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—osteoporosis	1.61e-05	2.61e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—osteoporosis	1.61e-05	2.61e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—osteoporosis	1.6e-05	2.6e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—osteoporosis	1.6e-05	2.59e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—osteoporosis	1.59e-05	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—osteoporosis	1.49e-05	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—osteoporosis	1.49e-05	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—osteoporosis	1.49e-05	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—osteoporosis	1.49e-05	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—osteoporosis	1.49e-05	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—osteoporosis	1.49e-05	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—osteoporosis	1.48e-05	2.4e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—osteoporosis	1.47e-05	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—osteoporosis	1.47e-05	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—osteoporosis	1.47e-05	2.38e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—osteoporosis	1.38e-05	2.24e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—osteoporosis	1.38e-05	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—osteoporosis	1.37e-05	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—osteoporosis	1.37e-05	2.22e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO1—osteoporosis	1.32e-05	2.15e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PSMA2—osteoporosis	1.31e-05	2.12e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PSMA5—osteoporosis	1.31e-05	2.12e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—osteoporosis	1.22e-05	1.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—osteoporosis	1.22e-05	1.97e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—osteoporosis	1.22e-05	1.97e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—osteoporosis	1.2e-05	1.95e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—osteoporosis	1.12e-05	1.82e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—osteoporosis	1.12e-05	1.82e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—osteoporosis	1.12e-05	1.82e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—osteoporosis	1.11e-05	1.8e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP19A1—osteoporosis	1.06e-05	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—osteoporosis	1.05e-05	1.7e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—osteoporosis	1.05e-05	1.7e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—osteoporosis	1.05e-05	1.7e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—osteoporosis	1.04e-05	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—osteoporosis	1.04e-05	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—osteoporosis	1.04e-05	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—osteoporosis	1.04e-05	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—osteoporosis	1.03e-05	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—osteoporosis	1.03e-05	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—osteoporosis	1.03e-05	1.67e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ADCY5—osteoporosis	8.65e-06	1.4e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GPX1—osteoporosis	8.62e-06	1.4e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—osteoporosis	7.96e-06	1.29e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—osteoporosis	7.86e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—osteoporosis	7.86e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—osteoporosis	7.86e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—osteoporosis	7.75e-06	1.26e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—POMC—osteoporosis	6.36e-06	1.03e-05	CbGpPWpGaD
